{"id":"W2910644531","doi":"10.1016/j.ejca.2018.12.006","title":"The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"CancerCare Manitoba; Ozmosis Research (Canada); Queen Elizabeth II Health Sciences Centre; Regional Municipality of Durham; Centre Hospitalier de l’Université de Montréal; London Health Sciences Centre; Ottawa Hospital; BC Cancer Agency; Princess Margaret Cancer Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"Pfizer","keywords":"Sunitinib; Medicine; Toxicity; Renal cell carcinoma; Dosing; Clinical endpoint; Internal medicine; Clinical trial; Phases of clinical research; Oncology; Adverse effect; Urology; Confidence interval; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002720586,0.0001996326,0.0006051831,0.00009635857,0.00009648729,0.00003029049,0.0002020208,0.0000270095,0.0001329744],"category_scores_gemma":[0.0002479274,0.0001129709,0.0002936878,0.0000930674,0.0001305711,0.00007405083,0.00002675277,0.0003350827,0.000008084761],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005384497,"about_ca_system_score_gemma":0.0003129391,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000006424099,"about_ca_topic_score_gemma":0.000003270857,"domain_scores_codex":[0.9972557,0.0007907554,0.001070475,0.0002143937,0.0004515906,0.0002170657],"domain_scores_gemma":[0.9971353,0.00103612,0.000898751,0.000331458,0.0003334215,0.0002649554],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8208541,0.005119008,0.004603988,0.0001463364,0.001228176,0.0004909902,0.001920679,0.0001705516,0.005378675,0.00007201323,0.001665472,0.15835],"study_design_scores_gemma":[0.6873713,0.1492633,0.06769154,0.0003761408,0.001128085,0.0001241228,0.0003328441,0.0001002988,0.02162156,0.00003408709,0.07169078,0.0002659649],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9929391,0.003088538,0.00004256846,0.001054802,0.0004053761,0.001322591,0.00005252041,0.00000501459,0.001089547],"genre_scores_gemma":[0.9967836,0.001037203,0.0005423787,0.0002760974,0.000813317,0.000007671115,0.00001298816,0.0000501314,0.000476638],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.158084,"threshold_uncertainty_score":0.4606821,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09894425372658124,"score_gpt":0.3957872506001386,"score_spread":0.2968429968735574,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}